Protara Q2 net loss $21.7M; guides ADVANCED-2 enrollment completion, THRIVE-3 interim results to 4Q 2026

Protara Therapeutics, Inc.

Q2 2026 net loss of $21.7M ($0.36/share) vs. $15.0M ($0.35/share) in Q2 2025.
Cash and equivalents of $161.9M at June 30, 2026; expected to fund operations into 2028.
ADVANCED-2 BCG-Unresponsive cohort enrollment completion expected 4Q 2026; ADVANCED-3 redesigned as exploratory trial.
STARBORN-1 showed 83% (10/12) clinical success, 100% (10/10) evaluable; BLA for TARA-002 in LMs expected 2H 2027.
R&D expenses rose to $17.0M from $10.8M YoY; THRIVE-3 interim results expected in 4Q 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.